Copy Link Print Information

Osimertinib mesylate

(Synonyms: AZD-9291 mesylate; Mereletinib mesylate)
194 Cited Publications
Customer Review

Based on 194 publication(s) in Google Scholar

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

For research use only. We do not sell to patients.

  • Purity: 99.97%
  • CAS No.: 1421373-66-1
  • Formula: C29H37N7O5S
  • Molecular Weight:595.71
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

  • Osimertinib mesylate Chemical Structure
    Osimertinib mesylate Chemical Structure
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
  • Experimental Validation Results for Osimertinib mesylate
CAS No.: 1421373-66-1
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Osimertinib mesylate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Osimertinib mesylate

More
Customer Validation & Images
WBCell Proliferation/Viability AssayIF
  • IF
  • IF
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All EGFR Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Osimertinib mesylate Chemical Structure
    Osimertinib mesylate Chemical Structure
    1/16
  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

    Customer Validation
     HCC827 (EGFR mutant) and NCI-H2228 (ALK-translocated) lung cancer cells were treated with 100 nM of the EGFR inhibitor Osimertinib or 500 nM of the ALK inhibitor alectinib for 72 h, respectively. Representative immunofluorescence images of E-cadherin were merged with DAPI. Scale bar, 10 μm.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

    Customer Validation
     HCC827 and NCI-H2228 cancer cell lines were treated with 100 nM Osimertinib, 500 nM alectinib or 50 nM trametinib for 72 h as indicated. Immunofluorescence images of Scrib were merged with DAPI. Scale bar, 10 μm.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

    Customer Validation
     Osimertinib-induced MRAS activation was abrogated by the addition of either SHP2 or SOS1 inhibitor in HCC827 cells. HCC827 cells were treated with 100 nM Osimertinib with or without 10 μM BI-3406 or 10 μM SHP099 for 72 h.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219.  [Abstract]

    Customer Validation
     Measurement of antiproliferation effects of AZD9291 (Osimertinib) (0.5-2 μM; 24 h) by EdU incorporation assay.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219.  [Abstract]

    Customer Validation
     U87 and U251 cells are exposed to indicated concentrations of AZD9291 (Osimertinib) for 24 h and then stimulated with EGF (100 ng/mL) for 30 min. Cell lysates are prepared and examined using Western blot analysis with indicated antibodies.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219.  [Abstract]

    Customer Validation
     U87 and U251 cells are treated with AZD9291 (Osimertinib) or CP-358774 for 4, 24 and 48 h. The expression level of p-ERK are assessed using Western blot analysis.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219.  [Abstract]

    Customer Validation
     GBM cells were treated by different concentrations of AZD9291 (Osimertinib) (0.625–20 μM) for 72 h. The cell viability was examined by CCK8 assay. Comparation of different sensitive of GBM cells to EGFR inhibitors (AZD9291, Erlotinib and Gefitinib).

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 Dec;40(12):1587-1595. [Abstract]

    Customer Validation
     MDAMB-453 cells are pre-treated with 10 μM MG132 for 1 h before treatment with the 20 μM AZD for 4 h. Cell lysates were used for SDS PAGE and Western blotting. AZD9291 disrupts the EZH2–EED interaction by binding to EZH2 directly

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2019 Apr;34(4):476-485. [Abstract]

    Customer Validation
     Protein levels of p-EGFR(Tyr1068), p-EGFR(Tyr1137), EGFR, p-STAT3, STAT3, p-AKT, AKT, p-p38 MAPK, and p-ERK MAPK are analyzed in GST-Der pII1-129-stimulated human epithelial cells with/without AZD-9291 treatment.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2019 Apr;34(4):476-485. [Abstract]

    Customer Validation
     Protein levels of p-EGFR(Tyr1068), p-EGFR(Tyr1137), EGFR, p-STAT3, STAT3, p-AKT, AKT, p-p38 MAPK, and p-ERK MAPK are analyzed in GST-Der pII1-129-stimulated human epithelial cells with/without AZD-9291 treatment.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2019 Apr;34(4):476-485. [Abstract]

    Customer Validation
     Protein levels of NF-κB and IκB are analyzed are analyzed in GST-Der pII1-129-stimulated human epithelial cells with/without AZD-9291 treatment.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4. [Abstract]

    Customer Validation
     Negligible increases in caspase-3 activity or PARP-1 cleavage is observed in H1975 NSCLC cells treated with DMSO, single agent PAC-1 (5 mM), or Osimertinib (Osi). In cells treated with PAC-1+Osimertinib, dramatic increases in caspase-3 activity is observed as early as 36 hr post treatment.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Mar 14;8(11):18359-18372. [Abstract]

    Customer Validation
     In all of the cell lines tested, AZD9291 (Osimertinib) significantly affects the phosphorylation of eIF4E, which presumably is due to its strong inhibitory activity against MNK2 kinase.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Mar 14;8(11):18359-18372. [Abstract]

    Customer Validation
     In all of the cell lines tested, AZD9291 (Osimertinib) significantly affects the phosphorylation of eIF4E, which presumably is due to its strong inhibitory activity against MNK2 kinase.

  • 1/16

    Osimertinib mesylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Oct 13;6(31):31313-22. [Abstract]

    Customer Validation
     Effect of PCI-32765, WZ4002, AZD9291 (Osimertinib) and CO1686 on EGFR phosphorylation of tyrosines 1068 and 1173 in EGFR-dependent cancer cell lines.

  • Osimertinib mesylate